Home › Funds › OBERWEIS ASSET MANAGEMENT INC/ › KNSA
OBERWEIS ASSET MANAGEMENT INC/ position in KNSA
KINIKSA PHARMACEUTICALS INTL · Health Care
OBERWEIS ASSET MANAGEMENT INC/ reported holding 410,908 shares of KNSA (KINIKSA PHARMACEUTICALS INTL) in its Q3 2026 13F filing — a position valued at US$30.7M, representing 0.69% of its reported portfolio and ranking #45 among its reported holdings. OBERWEIS ASSET MANAGEMENT INC/ has disclosed KNSA holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How OBERWEIS ASSET MANAGEMENT INC/'s KNSA position evolved
OBERWEIS ASSET MANAGEMENT INC/ first disclosed a stake in KNSA in Q3 2024 at 201,000 shares (US$5.0M). The position peaked in Q3 2026 at 410,908 shares, worth US$30.7M. Across 9 filings, OBERWEIS ASSET MANAGEMENT INC/ increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 410,908 shares valued at US$30.7M — a reduction of -2,126 shares quarter over quarter.. Notable position changes include a 29% increase in Q2 2025 (shares rose 40% over the following quarter), a 30% increase in Q2 2026 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 201.00K | $5.02M | New |
| Q4 2024 | 237.20K | $4.69M | Add |
| Q1 2025 | 237.20K | $5.27M | Hold |
| Q2 2025 | 305.20K | $8.44M | Add |
| Q3 2025 | 305.20K | $11.85M | Hold |
| Q4 2025 | 312.80K | $12.90M | Add |
| Q1 2026 | 318.63K | $15.34M | Add |
| Q2 2026 | 413.03K | $26.41M | Add |
| Q3 2026 | 410.91K | $30.66M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KNSA and 13F data
KNSA (KINIKSA PHARMACEUTICALS INTL) is a Health Care company. 49 other funds we track also report a position in KNSA — the largest reported positions include Rubric Capital Management LP (US$255.8M), BAKER BROS. ADVISORS LP (US$181.3M), TANG CAPITAL MANAGEMENT LLC (US$144.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KNSA
- Rubric Capital Management LP 4.00M sh · $255.79M · Q2 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $181.28M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 2.26M sh · $144.52M · Q2 2026
- Spruce Street Capital LP 918.07K sh · $68.50M · Q3 2026
- RICE HALL JAMES & ASSOCIATES, LLC 466.05K sh · $34.77M · Q3 2026
- ORBIMED ADVISORS LLC 420.60K sh · $26.90M · Q2 2026
- Penn Capital Management Company, LLC 347.66K sh · $25.97M · Q3 2026
- Soleus Capital Management, L.P. 246.35K sh · $15.75M · Q2 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 202.02K sh · $15.07M · Q3 2026
- ArrowMark Colorado Holdings LLC 198.67K sh · $14.82M · Q3 2026
More on OBERWEIS ASSET MANAGEMENT INC/
FAQ
How long has OBERWEIS ASSET MANAGEMENT INC/ held KNSA?
OBERWEIS ASSET MANAGEMENT INC/ has disclosed KNSA holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is OBERWEIS ASSET MANAGEMENT INC/'s current position in KNSA?
As of Q3 2026, OBERWEIS ASSET MANAGEMENT INC/ holds 410.91K shares of KNSA (KINIKSA PHARMACEUTICALS INTL), valued at $30.66M, representing 0.69% of its reported portfolio and ranking #45.
Has OBERWEIS ASSET MANAGEMENT INC/ been buying or selling KNSA?
In the latest 13F filing (Q3 2026), OBERWEIS ASSET MANAGEMENT INC/ reduced its position in KNSA. The position peaked in Q3 2026 at 410.91K shares.
Which other funds hold KNSA?
Other major institutional holders of KNSA include Rubric Capital Management LP, BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.